Drug Trial Radar · NCT04225871
Open-Label Extension of Zilucoplan in Subjects With Generalized Myasthenia Gravis
Last checked: Nov 20, 2026Latest source record: Oct 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
200
Actual
Start
Dec 23, 2019
Primary completion
Jul 31, 2026
Study completion Jul 31, 2026
Sponsor
- Lead sponsor
- UCB Biopharma SRLUCB
- Sponsor type
- Industry
- First posted
- Jan 13, 2020
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The RAISE-XT study is an open-label extension study to evaluate the long-term efficacy, safety, and tolerability of zilucoplan in subjects with gMG who have previously participated in a qualifying Ra Pharmaceuticals sponsored zilucoplan study.
Conditions
- Generalized Myasthenia Gravis
Interventions
zilucoplan (RA101495)Drug
Daily subcutaneous (SC) injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of treatment-emergent adverse events (TEAEs)Time frame: From Baseline (Day 1) to Safety Follow-Up Visit (up to 36 months)
Locations
70 sites in 10 countries. Site status is shown where the registry gives one.
Mg0011 41
Mobile, Alabama
Mg0011 116
Phoenix, Arizona
Mg0011 31
Irvine, California
MG0011 4
Los Angeles, California
Mg0011 220
Pasadena, California
Mg0011 160
San Francisco, California
Mg0011 24
New Haven, Connecticut
Mg0011 27
Washington D.C., District of Columbia
Mg0011 25
Tampa, Florida
Mg0011 135
Augusta, Georgia
Mg0011 188
Glenview, Illinois
Mg0011 156
Indianapolis, Indiana
Mg0011 32
Kansas City, Kansas
Mg0011 33
Detroit, Michigan
Mg0011 49
East Lansing, Michigan
Mg0011 134
Columbia, Missouri
Mg0011 117
Las Vegas, Nevada
Mg0011 30
Buffalo, New York
Mg0011 123
Great Neck, New York
Mg0011 23
New York, New York
Mg0011 47
New York, New York
Mg0011 22
Chapel Hill, North Carolina
Mg0011 122
Cleveland, Ohio
Mg0011 38
Columbus, Ohio
Mg0011 40
Pittsburgh, Pennsylvania
Mg0011 128
Charleston, South Carolina
Mg0011 28
Cordova, Tennessee
Mg0011 131
Austin, Texas
Mg0011 19
Dallas, Texas
Mg0011 39
Salt Lake City, Utah
Mg0011 164
Charlottesville, Virginia
Mg0011 154
Seattle, Washington
Mg0011 45
Milwaukee, Wisconsin
Mg0011 11
Montreal, Canada
Mg0011 204
Lille, France
Mg0011 118
Nice, France
Mg0011 105
Paris, France
Mg0011 137
Strasbourg, France
Mg0011 150
Göttingen, Germany
Mg0011 129
Tübingen, Germany
Showing 40 of 70 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.